Dual-use blood sampling device for modern defense and disaster medicine - InstaSep™
| Reference number | |
| Coordinator | SampleFacts AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2025 - August 2026 |
| Status | Ongoing |
| Venture | Civil-military synergies |
| Call | Acceleration of civil-military innovations by 2025 |
Purpose and goal
The project aims to establish the SampleFacts InstaSep™ blood separation device as a dual-use application platform for biosafety and defense medicine as well as serving civilian markets. The purpose is to enable rapid, reliable plasma separation without centrifugation, directly at the point of sampling, even under rigid conditions. The objective is to demonstrate that InstaSep™ can support field diagnostics, and monitoring when conventional sampling infrastructure is unavailable.
Expected effects and result
The outcome of the project is to adapt and validate the InstaSep™ for diverse biomarker applications in both in civilian systems, humanitarian operations, and military medicine contexts to demonstrate the dual-use applicability in decentralized diagnostics. By enabling immediate separation of blood, InstaSep™ enables retrospective analysis, since both fractions remain stable at ambient temperature. Transport of the samples requires neither cold chain nor any biohazardous liquid handling.
Planned approach and implementation
The nine-month project comprises three phases. Phase 1 will assess feasibility through user interviews in military and civilian settings, definition of operational requirements, and conducting market and regulatory analyses. In phase 2, validation of performance and analyte stability of InstaSep™ under extreme conditions will be performed. Phase 3 will include pilot testing, market entry planning, and risk mitigation.